SCHEMBL2015299

SCHEMBL2015299

CC(C)(O)CNc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
ALDH1A1 P00352 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
IDH2 P48735 2/20 0.43
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
PDK1 Q15118 2/20 0.40
PDK2 Q15119 2/20 0.40
PDK3 Q15120 2/20 0.40
PDK4 Q16654 2/20 0.40
DPP7 Q9UHL4 1/20 0.39
FFAR1 O14842 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
IDO1 P14902 1/20 0.39
TSHR P16473 1/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3732806 0.81 MAPT (0.48) MAPTALDH1A1SIGMAR1MEN1CYP1A2
SCHEMBL28333306 0.81 CYP2C19 (0.53) MAPTALDH1A1SIGMAR1IDH2MEN1
SCHEMBL10126871 0.80 MAPT (0.54) MAPTALDH1A1MEN1KMT2AFFAR1
Hydrochloric Acid SCHEMBL17710416 0.79 MAPT (0.46) MAPTALDH1A1SIGMAR1MEN1CYP1A2
SCHEMBL21379732 0.78 MAPT (0.41) MAPTALDH1A1SIGMAR1CYP2C19L3MBTL1
SCHEMBL8613449 0.78 KMT2A (0.42) MAPTALDH1A1IDH2MEN1CYP3A4
SCHEMBL17963320 0.78 MAPT (0.42) MAPTALDH1A1SIGMAR1CYP1A2CYP3A4
SCHEMBL6702352 0.77 TAAR1 (0.46) MAPTALDH1A1SIGMAR1MEN1CYP1A2
SCHEMBL9323396 0.77 ALDH1A1 (0.44) MAPTALDH1A1SIGMAR1MEN1CYP1A2
SCHEMBL30288278 0.77 ALDH1A1 (0.44) MAPTALDH1A1SIGMAR1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed
EP-2513069-B1 ANTIFUNGAL COMPOUNDS UNIV LEUVEN KATH (BE) 2014-10-15 EP disclosed
EP-2569309-A1 HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES Bayer Intellectual Property GmbH (DE) 2013-03-20 EP disclosed
EP-2513069-A1 ANTIFUNGAL COMPOUNDS Katholieke Universiteit Leuven (BE) 2012-10-24 EP disclosed
US-20120252801-A1 ANTIFUNGAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-10-04 US disclosed
WO-2011141325-A1 HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-17 WO disclosed
US-8022059-B2 Indazole acrylic acid amide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-20 US disclosed
US-8022059-B2 Indazole acrylic acid amide compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-20 US disclosed
WO-2011072345-A1 ANTIFUNGAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2011-06-23 WO disclosed
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 US disclosed
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 US disclosed
EP-2192116-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2010-06-02 EP disclosed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP disclosed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO disclosed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256108-A1 INDAZOLE ACRYLIC ACID AMIDE COMPOUND KCNH2, KCNH3, KCNJ11 MAPT 4800/4885ALDH1A1 711/4885SIGMAR1 756/4885
US-20120252801-A1 ANTIFUNGAL COMPOUNDS ERG28, DPM1, CYP51A1 MAPT 809/4885ALDH1A1 2899/4885SIGMAR1 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.